Therapy Areas: Oncology
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
30 June 2025 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq:HCM) (AIM:HCM) (HKEX:13) announced on Monday that it has received approval from the China National Medical Products Administra...
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
30 June 2025 - Chinese biopharmaceutical company Mabwell (SH:688062) announced on Friday that its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim...
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
27 June 2025 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced late Thursday that the US Food and Drug Administration has approved updated labels for its two CAR T cell therapies, ...
Porton Advanced signs MOU with EVA Pharma for expanded Middle East and Africa CAR T-cell therapy access
27 June 2025 - Porton Advanced Solutions, a US-based global cell and gene therapy CDMO service provider, and EVA Pharma, an Egypt-based pharmaceutical company, announced on Thursday the signing of Mem...
Biovica secures European patent for biomarker use in immuno-oncology
26 June 2025 - Biovica International AB (Nasdaq First North Premier Growth Market:BIOVIC-B), a supplier of blood-based biomarker assays to monitor cancer progression, revealed on Thursday that it has ...
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
26 June 2025 - CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a China-based company involved in developing innovative CAR T-cell therapies, announced on Wednesday that the National Medic...